Chimeric Antigen Receptor-T Cell Therapy with Breast Cancer

Tianyue Zhang

doi:10.54097/nv88mv74

Authors

Tianyue Zhang

DOI:

https://doi.org/10.54097/nv88mv74

Keywords:

CAR-T, breast cancer, cancer treatment.

Abstract

Breast cancer (BC) poses an increasingly serious threat to the women's health. In 2020, there will be 2.26 million new cases of BC, surpassing lung cancer for the first time and becoming the world's "first cancer". BC is distinguished by its intense invasion, extreme malignancy, and dismal outlook. High attention is needed. Chimera Antigen Receptor-T(CAR-T) has the potential to modify T cells and direct them towards particular tumor cells. It has made unheard-of advancements in hematological cancers since it was originally authorized for use in B-cell derived malignant tumors in 2017. In recent years, it has greatly reshaped the pattern of cancer treatment. At present, accumulated evidence suggests that this therapy may become the feasible treatment strategy for the solid tumors. This review will describe the main goals of this therapy for BC, list the challenges it faces, and offer the solutions to these problems, offering a unique strategy for breast cancer treatment.

Downloads

Download data is not yet available.

References

Zhu Y, Zhu X, Wei X, Tang C, Zhang W. HER2-targeted therapies in gastric cancer. Biochim Biophys Acta Rev Cancer. 2021; 1876 (1): 188549.

Yang YH, Liu JW, Lu C, Wei JF. CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application. Int J Biol Sci. 2022; 18 (6): 2609 - 2626.

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011; 331: 1559 – 64.

Voutsadakis IA. HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer. Clin Transl Oncol. 2019; 21: 539 – 55.

Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2: 127 – 37.

Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61 - 70.

Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003; 27: 1418 – 28.

Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH. et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2013; 1: 43 – 53.

Newick K, O'Brien S, Moon E, Albelda SM. CAR T Cell Therapy for Solid Tumors. Annu Rev Med. 2017; 68: 139 – 52.

Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C. et al. Current Progress in CAR-T Cell Therapy for Solid Tumors. Int J Biol Sci. 2019; 15: 2548 – 60.